Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers-Reference-Cited by-同舟云学术

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers

Published:2013-04-08 Issue:5 Volume:75 Page:1240-1254
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Stoch S. Aubrey¹,Zajic Stefan¹,Stone Julie A.¹,Miller Deborah L.¹,van Bortel Lucas²,Lasseter Kenneth C.³,Pramanik Barnali¹,Cilissen Caroline⁴,Liu Qi¹,Liu Lida¹,Scott Boyd B.¹,Panebianco Deborah¹,Ding Yu¹,Gottesdiener Keith¹,Wagner John A.¹

Affiliation:

1. Merck Sharp & Dohme Corp.; Whitehouse Station; NJ; USA

2. Department of Pharmacology; Ghent University; Ghent; Belgium

3. Clinical Pharmacology of Miami Inc.; Miami; FL; USA

4. Merck Sharp & Dohme Corp.; Clinical Pharmacology Brussels; Brussels; Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2012.04471.x/fullpdf

Reference29 articles.